@article{Hussey2021,
abstract = {A novel proxy for the Delta variant, RNA-dependent RNA polymerase target delay in the Seegene Allplex™ 2019-nCoV PCR assay, was associated with higher mortality (adjusted Odds Ratio 1.45 [95{\%}CI 1.13-1.86]), compared to presumptive Beta infection, in the Western Cape, South Africa (April-July 2021). Prior diagnosed infection and vaccination were protective. {\#}{\#}{\#} Competing Interest Statement The authors have declared no competing interest. {\#}{\#}{\#} Funding Statement This study was funded by the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill {\&} Melinda Gates and the Minderoo Foundations (INV-017293), and by a research Flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI). Additional support was provided by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC0010218), the UK Medical Research Council (FC0010218), and the Wellcome Trust (FC0010218) as well as Wellcome (203135, 222574). {\#}{\#}{\#} Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the University of Cape Town Research Ethics Committee (HREC 460/2020). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors},
author = {Hussey, Hannah and Davies, Mary-Ann and Heekes, Alexa and Williamson, Carolyn and Valley-Omar, Ziyaad and Hardie, Diana and Korsman, Stephen and Doolabh, Deelan and Preiser, Wolfgang and Maponga, Tongai and Iranzadeh, Arash and Engelbrecht, Susan and Wasserman, Sean and Schrueder, Neshaad and Boloko, Linda and Symons, Greg and Raubenheimer, Peter and Viljoen, Abraham and Parker, Arifa and Cohen, Cheryl and Jassat, Waasila and Lessells, Richard and Wilkinson, Robert J and Boulle, Andrew and Hsiao, Nei-yuan},
doi = {10.1101/2021.10.23.21265412},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Hussey et al. - 2021 - Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp targe.pdf:pdf},
journal = {medRxiv},
keywords = {OA,fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,original},
month = {oct},
pages = {2021.10.23.21265412},
publisher = {Cold Spring Harbor Laboratory Press},
title = {{Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy}},
url = {https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1 https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1.abstract},
volume = {13},
year = {2021}
}

{"_id":"k5QZAZzxW86nfLrB6","bibbaseid":"hussey-davies-heekes-williamson-valleyomar-hardie-korsman-doolabh-etal-highermortalityassociatedwiththesarscov2deltavariantinthewesterncapesouthafricausingrdrptargetdelayasaproxy-2021","author_short":["Hussey, H.","Davies, M.","Heekes, A.","Williamson, C.","Valley-Omar, Z.","Hardie, D.","Korsman, S.","Doolabh, D.","Preiser, W.","Maponga, T.","Iranzadeh, A.","Engelbrecht, S.","Wasserman, S.","Schrueder, N.","Boloko, L.","Symons, G.","Raubenheimer, P.","Viljoen, A.","Parker, A.","Cohen, C.","Jassat, W.","Lessells, R.","Wilkinson, R. J","Boulle, A.","Hsiao, N."],"bibdata":{"bibtype":"article","type":"article","abstract":"A novel proxy for the Delta variant, RNA-dependent RNA polymerase target delay in the Seegene Allplex™ 2019-nCoV PCR assay, was associated with higher mortality (adjusted Odds Ratio 1.45 [95%CI 1.13-1.86]), compared to presumptive Beta infection, in the Western Cape, South Africa (April-July 2021). Prior diagnosed infection and vaccination were protective. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and the Minderoo Foundations (INV-017293), and by a research Flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI). Additional support was provided by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC0010218), the UK Medical Research Council (FC0010218), and the Wellcome Trust (FC0010218) as well as Wellcome (203135, 222574). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the University of Cape Town Research Ethics Committee (HREC 460/2020). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors","author":[{"propositions":[],"lastnames":["Hussey"],"firstnames":["Hannah"],"suffixes":[]},{"propositions":[],"lastnames":["Davies"],"firstnames":["Mary-Ann"],"suffixes":[]},{"propositions":[],"lastnames":["Heekes"],"firstnames":["Alexa"],"suffixes":[]},{"propositions":[],"lastnames":["Williamson"],"firstnames":["Carolyn"],"suffixes":[]},{"propositions":[],"lastnames":["Valley-Omar"],"firstnames":["Ziyaad"],"suffixes":[]},{"propositions":[],"lastnames":["Hardie"],"firstnames":["Diana"],"suffixes":[]},{"propositions":[],"lastnames":["Korsman"],"firstnames":["Stephen"],"suffixes":[]},{"propositions":[],"lastnames":["Doolabh"],"firstnames":["Deelan"],"suffixes":[]},{"propositions":[],"lastnames":["Preiser"],"firstnames":["Wolfgang"],"suffixes":[]},{"propositions":[],"lastnames":["Maponga"],"firstnames":["Tongai"],"suffixes":[]},{"propositions":[],"lastnames":["Iranzadeh"],"firstnames":["Arash"],"suffixes":[]},{"propositions":[],"lastnames":["Engelbrecht"],"firstnames":["Susan"],"suffixes":[]},{"propositions":[],"lastnames":["Wasserman"],"firstnames":["Sean"],"suffixes":[]},{"propositions":[],"lastnames":["Schrueder"],"firstnames":["Neshaad"],"suffixes":[]},{"propositions":[],"lastnames":["Boloko"],"firstnames":["Linda"],"suffixes":[]},{"propositions":[],"lastnames":["Symons"],"firstnames":["Greg"],"suffixes":[]},{"propositions":[],"lastnames":["Raubenheimer"],"firstnames":["Peter"],"suffixes":[]},{"propositions":[],"lastnames":["Viljoen"],"firstnames":["Abraham"],"suffixes":[]},{"propositions":[],"lastnames":["Parker"],"firstnames":["Arifa"],"suffixes":[]},{"propositions":[],"lastnames":["Cohen"],"firstnames":["Cheryl"],"suffixes":[]},{"propositions":[],"lastnames":["Jassat"],"firstnames":["Waasila"],"suffixes":[]},{"propositions":[],"lastnames":["Lessells"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Wilkinson"],"firstnames":["Robert","J"],"suffixes":[]},{"propositions":[],"lastnames":["Boulle"],"firstnames":["Andrew"],"suffixes":[]},{"propositions":[],"lastnames":["Hsiao"],"firstnames":["Nei-yuan"],"suffixes":[]}],"doi":"10.1101/2021.10.23.21265412","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Hussey et al. - 2021 - Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp targe.pdf:pdf","journal":"medRxiv","keywords":"OA,fund_ack,original","mendeley-tags":"OA,fund_ack,original","month":"oct","pages":"2021.10.23.21265412","publisher":"Cold Spring Harbor Laboratory Press","title":"Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy","url":"https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1 https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1.abstract","volume":"13","year":"2021","bibtex":"@article{Hussey2021,\r\nabstract = {A novel proxy for the Delta variant, RNA-dependent RNA polymerase target delay in the Seegene Allplex™ 2019-nCoV PCR assay, was associated with higher mortality (adjusted Odds Ratio 1.45 [95{\\%}CI 1.13-1.86]), compared to presumptive Beta infection, in the Western Cape, South Africa (April-July 2021). Prior diagnosed infection and vaccination were protective. {\\#}{\\#}{\\#} Competing Interest Statement The authors have declared no competing interest. {\\#}{\\#}{\\#} Funding Statement This study was funded by the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill {\\&} Melinda Gates and the Minderoo Foundations (INV-017293), and by a research Flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI). Additional support was provided by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC0010218), the UK Medical Research Council (FC0010218), and the Wellcome Trust (FC0010218) as well as Wellcome (203135, 222574). {\\#}{\\#}{\\#} Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the University of Cape Town Research Ethics Committee (HREC 460/2020). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors},\r\nauthor = {Hussey, Hannah and Davies, Mary-Ann and Heekes, Alexa and Williamson, Carolyn and Valley-Omar, Ziyaad and Hardie, Diana and Korsman, Stephen and Doolabh, Deelan and Preiser, Wolfgang and Maponga, Tongai and Iranzadeh, Arash and Engelbrecht, Susan and Wasserman, Sean and Schrueder, Neshaad and Boloko, Linda and Symons, Greg and Raubenheimer, Peter and Viljoen, Abraham and Parker, Arifa and Cohen, Cheryl and Jassat, Waasila and Lessells, Richard and Wilkinson, Robert J and Boulle, Andrew and Hsiao, Nei-yuan},\r\ndoi = {10.1101/2021.10.23.21265412},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Hussey et al. - 2021 - Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp targe.pdf:pdf},\r\njournal = {medRxiv},\r\nkeywords = {OA,fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,original},\r\nmonth = {oct},\r\npages = {2021.10.23.21265412},\r\npublisher = {Cold Spring Harbor Laboratory Press},\r\ntitle = {{Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy}},\r\nurl = {https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1 https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1.abstract},\r\nvolume = {13},\r\nyear = {2021}\r\n}\r\n","author_short":["Hussey, H.","Davies, M.","Heekes, A.","Williamson, C.","Valley-Omar, Z.","Hardie, D.","Korsman, S.","Doolabh, D.","Preiser, W.","Maponga, T.","Iranzadeh, A.","Engelbrecht, S.","Wasserman, S.","Schrueder, N.","Boloko, L.","Symons, G.","Raubenheimer, P.","Viljoen, A.","Parker, A.","Cohen, C.","Jassat, W.","Lessells, R.","Wilkinson, R. J","Boulle, A.","Hsiao, N."],"key":"Hussey2021","id":"Hussey2021","bibbaseid":"hussey-davies-heekes-williamson-valleyomar-hardie-korsman-doolabh-etal-highermortalityassociatedwiththesarscov2deltavariantinthewesterncapesouthafricausingrdrptargetdelayasaproxy-2021","role":"author","urls":{"Paper":"https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1 https://www.medrxiv.org/content/10.1101/2021.10.23.21265412v1.abstract"},"keyword":["OA","fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","y6ojaHcuarkmc4yRQ"],"keywords":["oa","fund_ack","original"],"search_terms":["higher","mortality","associated","sars","cov","delta","variant","western","cape","south","africa","using","rdrp","target","delay","proxy","hussey","davies","heekes","williamson","valley-omar","hardie","korsman","doolabh","preiser","maponga","iranzadeh","engelbrecht","wasserman","schrueder","boloko","symons","raubenheimer","viljoen","parker","cohen","jassat","lessells","wilkinson","boulle","hsiao"],"title":"Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy","year":2021}